Fondaparinux sodium: A review of its use in the prevention of venous thromboembolism following major orthopaedic surgery

Drugs

Volumn 64, Issue 14, 2004, Pages 1575-1596

  Reynolds, Neil A ^a   Perry, Caroline M ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Deep vein thrombosis; Fondaparinux sodium; Pharmacodynamics; Pharmacoeconomics; Pharmacokinetics; Pulmonary embolism; Therapeutic use; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; FONDAPARINUX; LOW MOLECULAR WEIGHT HEPARIN;

BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; HIP ARTHROPLASTY; HIP FRACTURE; HIP SURGERY; HUMAN; KNEE SURGERY; META ANALYSIS; ORTHOPEDIC SURGERY; POSTOPERATIVE COMPLICATION; PROPHYLAXIS; REVIEW; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

CLINICAL TRIALS; HUMANS; ORTHOPEDIC PROCEDURES; POLYSACCHARIDES; VENOUS THROMBOSIS;

EID: 3242760719     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464140-00005     Document Type: Review

References (78)

1. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119 (1 Suppl.): 132S-75S
2. Hyers TM. Management of venous thromboembolism: past, present, and future. Arch Intern Med 2003 Apr 14; 163 (7): 759-68
3. Bick RL. Proficient and cost-effective approaches for the prevention and treatment of venous thrombosis and thromboembolism. Drugs 2000 Sep; 60 (3): 575-95
4. Petitou M, Duchaussoy P, Herbert J-M, et al. The synthetic pentasaccharide fondaparinux: first in the class of antithrombotic agents that selectively inhibit coagulation factor Xa. Semin Thromb Hemost 2002; 28 (4): 393-402
5. Agnelli G, Bergqvist D, Cohen A, et al. A randomized double-blind study to compare the efficacy and safety of postoperative fondaparinux (Arixtra®) and preoperative dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the PEGASUS study [abstract no. 40]. Blood 2003 Nov; 102(11 Pt 1): 15a
6. Cohen AT, Davidson BL, Gallus AS, et al. Fondaparinux for the prevention of VTE in acutely ill medical patients [abstract no. 42]. Blood 2003 Nov; 102 (11 Pt 1): 15a
7. The Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 2003 Oct; 349 (18): 1695-702
8. Büller HR, Davidson BL, Decousus H, et al., for The Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. Ann Intern Med 2004 Jun 1; 140 (11): 867-73
9. Coussement PK, Bassand J-P, Convens C, et al. A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction: the PENTALYSE study. Eur Heart J 2001 Sep; 22 (18): 1716-24
10. Vuillemenot A, Schiele F, Meneveau N, et al. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent: a pilot study in the setting of coronary angioplasty. Thromb Haemost 1999; 81 (2): 214-20
11. Keam SJ, Goa KL. Fondaparinux sodium. Drugs 2002; 62 (11): 1673-85; discussion 1686-7
12. Herbert JM, Petitou M, Lormeau JC, et al. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent. Cardiovasc Drug Rev 1997; 15 (1): 1-26
13. Walenga JM, Jeske WP, Bara L, et al. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997; 86 (1): 1-36
14. Samama MM, Bara L, Walenga J. Comparative mechanism of action and pharmacokinetics of pentasaccharide and LMW heparins. 16th International Congress on Thrombosis; 2000 May 5-8; Porto, 99-102
15. Sanofi-Synthelabo. Arixtra summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/ [Accessed 2003 Sep 23]
16. Messmore Jr HL, Griffin B, Fareed J, et al. In vitro studies of the interaction of heparin, low molecular weight heparin and heparinoids with platelets. Ann N Y Acad Sci 1989; 556: 217-31
17. Boneu B, Necciari J, Cariou R, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ORG31540) with high affinity to antithrombin III in man. Thromb Haemost 1995; 74 (6): 1468-73
18. Herbert JM, Hérault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998 Jun; 91 (11): 4197-205
19. Petitou M, Duchaussoy P, Jaurand G, et al. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107A/ORG 31540). J Med Chem 1997 May 23; 40 (11): 1600-7
20. Lormeau JC, Herault JP, Gaich C, et al. Determination of the anti-factor Xa activity of the synthetic pentasaccharide SR 90107A/ORG 31540 and of two structural analogues. Thromb Res 1997 Jan 1; 85 (1): 67-75
21. Bendetowicz AV, Bara L, Samama MM. The inhibition of intrinsic prothrombinase and its generation by heparin and four derivatives in prothrombin poor plasma. Thromb Res 1990; 58: 445-54
22. Brufatto N, Ward A, Nesheim ME. Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex. J Thromb Haemost 2003; 1: 1258-63
23. Herbert JM, Hérault JP, Bernat A, et al. Biochemical and pharmacological properties of SANORG 32701: comparison with the 'synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin. Circ Res 1996; 79 (3): 590-600
24. Walenga JM, Petitou M, Lormeau JC, et al. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 1987; 46: 187-98
25. Carrie D, Caranobe C, Saivin S, et al. Pharmacokinetic and antithrombotic properties of two pentasaccharides with high affinity to antithrombin III in the rabbit: comparison with CY216. Blood 1994; 84 (8): 2571-7
26. Lormeau JC, Herault JP, Herbert JM. Antithrombin-mediated inhibition of factor VIIa-tissue factor complex by the synthetic pentasaccharide representing the heparin binding site to antithrombin. Thromb Haemost 1996 Jul; 76 (1): 5-8
27. Gerotziafas GT, Bara L, Bloch MF, et al. Comparative effects of synthetic pentasaccharide, low-molecular-weight heparin, unfractionated heparin and recombinant hirudin on the generation of factor VIIa and prothrombin activation after coagulation of human plasma. Blood Coagul Fibrinolysis 1998; 9 (7): 571-80
28. Pieters J, Lindhout T, Willems G. Heparin-stimulated inhibition of factor IXa generation and factor IXa neutralization in plasma. Blood 1990 Aug 1; 76 (3): 549-54
29. Wiebe EM, Stafford AR, Fredenburgh JC, et al. Mechanism of catalysis of inhibition of factor IXa by antithrombin in the presence of heparin or pentasaccharide. J Biol Chem 2003 Sep 12; 278 (37): 35767-74
30. a by antithrombin III/heparin during factor X activation. J Biol Chem 1988 Oct 25; 263 (30): 15313-8
31. Hérault JP, Gaich C, Bono F, et al. The structure of synthetic oligosaccharides in relation to factor IXa inhibition. Thromb Haemost 2002; 88 (3): 432-5
32. Lormeau JC, Herault JP. The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa. Thromb Haemost 1995; 74 (6): 1474-7
33. Horne 3rd MK, Chao ES. The effect of molecular weight on heparin binding to platelets. Br J Haematol 1990; 74 (3): 306-12
34. Amiral J, Lormeau JC, Marfaing-Koka A, et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997; 8 (2): 114-7
35. Savi P, Chong B, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent anti-platelet antibodies. A blinded comparative multicenter study with unfractionated heparin [abstract no. 1145]. Blood 2003 Nov; 102 (11 Pt 1): 319a
36. Ahmad S, Jeske WP, Walenga JM, et al. Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin App Thromb Hemost 1999; 5 (4): 259-66
37. Walenga JM, Fareed J. Relative contribution of factor Xa and factor IIa. Inhibition in the mediation of the antithrombotic actions of LMWHs and synthetic heparin pentasaccharides. Thromb Haemorrh Disord 1991; 3 (2): 53-9
38. Pottier P, Planchon B, Truchaud F, et al. Efficacy of pentasaccharide on a prethrombosis model based on a calibrated stasis by the increase in up-stream venous pressure. Blood Coagul Fibrinolysis 2003; 14 (6): 587-91
39. Iqbal O, Silver P, Walenga JM, et al. Neutralization of the anticoagulant effect of a synthetic heparinomimetic (pentasaccharide) by heparinase I: potential clinical implications [abstract no. P2246]. 18th Congress of the International Society on Thrombosis and Haemostasis; 2001 Jul 6-12; Paris
40. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106 (20): 2550-4
41. Donat F, Duret JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet 2002; 41 Suppl. 2: 1-9
42. Ollier C, Faaij RA, Santoni A, et al. Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers. Clin Pharmacokinet 2002; 41 Suppl. 2: 31-7
43. Faaij RA, Burggraaf J, Schoemaker RC, et al. Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. Br J Clin Pharmacol 2002; 54 (3): 304-8
44. Mant T, Fournié P, Ollier C, et al. Absence of interaction of fondaparinux sodium with digoxin in healthy volunteers. Clin Pharmacokinet 2002; 41 Suppl. 2: 39-45
45. Paolucci F, Claviés MC, Donat F, et al. Fondaparinux sodium mechanism of action: identification of specific binding to purified and human plasma-derived proteins. Clin Pharmacokinet 2002; 41 Suppl. 2: 11-8
46. Lagrange F, Vergnes C, Brun JL, et al. Absence of placental transfer of pentasaccharide (fondaparinux, Arixtra®) in the dually perfused human cotyledon in vitro. Thromb Haemost 2002; 87 (5): 831-5
47. Lieu C, Shi J, Donat F, et al. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of concomitant drugs. Clin Pharmacokinet 2002; 41 Suppl. 2: 19-26
48. Lassen MR, Bauer KA, Eriksson BI, et al., for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002 May 18; 359: 1715-20
49. Turpie AGG, Bauer KA, Eriksson BI, et al., for the PENTATHLON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002 May 18; 359: 1721-6
50. Bauer KA, Eriksson BI, Lassen MR, et al., for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001 Nov; 345 (18): 1305-10
51. Eriksson BI, Bauer KA, Lassen MR, et al., for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001 Nov; 345 (18): 1298-304
52. Eriksson BI, Lassen MR, for the PENTasaccharide in HIp-FRActure Surgery Plus (PENTHIFRA Plus) Investigators. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003 Jun 9; 163: 1337-42
53. Turpie AGG, Gallus AS, Hoek JA, et al., for the Pentasaccharide Investigators. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med 2001 Mar 1; 344 (9): 619-25
54. Turpie AGG, Bauer KA, Eriksson BI, et al., for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double- blind studies. Arch Intern Med 2002 Sep 9; 162 (16): 1833-40
55. Turpie AGG, Eriksson BI, Lassen MR, et al. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery. J South Orthop Assoc 2002 Winter; 11 (4): 182-8
56. Organon Sanofi-Synthelabo LLC. Arixtra® (fondaparinux sodium) injection prescribing information [online]. Available from URL: http://www.fda.gov/cder/approval/index.htm [Accessed 2003 May 11]
57. Turpie A, Bauer K, Eriksson B, et al., on behalf of the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Efficacy and safety of fondaparinux in major orthopedic surgery according to the timing of its first administration [letter]. Thromb Haemost 2003 Aug; 90 (2): 364-6
58. Lassen M, Bauer KA, Eriksson BI, et al. Absence of transaminase increase after 4-week administration of fondaparinux (Arixtra®), a new synthetic and selective inhibitor of factor Xa, in the PENTHIFRA-PLUS study [abstract no. P2052]. J Thromb Haemost 2003; 1 Suppl. 1: P2052
59. Gordois A, Posnett J, Borris L, et al. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. J Thromb Haemost 2003 Oct; 1 (10): 2167-74
60. Sullivan SD, Davidson BL, Kahn SR, et al. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics 2004; 22 (9): 605-20
61. Wade WE, Spruill WJ, Leslie RB. Cost analysis: fondaparinux versus preoperative and postoperative enoxaparin as venous thromboembolic event prophylaxis in elective hip arthroplasty. Am J Orthop 2003 Apr; 32 (4): 201-5
62. Spruill WJ, Wade WE, Leslie RB. A cost analysis of fondaparinux versus enoxaparin in total knee arthroplasty. Am J Ther 2004; 11 (1): 3-8
63. Annemans L, De Groot K. Cost-effectiveness of fondaparinux (Arixtra®) compared with enoxaparin as prophylaxis against venous thromboembolism following major orthopedic surgery [abstract no. P2053]. 19th Congress of the International Society on Thrombosis and Haemostasis; 2003 Jul 12-18; Birmingham
64. Slof J, Magaz S, Badia X. Clinical and economic outcomes of fondaparinux vs. enoxaparin in the prophylaxis of venous thromboembolism after major orthopedic surgery in Spain [poster]. 6th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2003 Nov 9-11; Barcelona
65. Stumpo C, Kahn S, Martineau J, et al. Pharmacoeconomic analysis of fondaparinux for the prevention of thromboembolic events in orthopedic surgical patients [abstract]. Can J Hosp Pharm 2003 Aug; 56 Suppl. 3: 29
66. Sullivan SD, Kahn SR, Muntz JE. Fondaparinux is cost-effective compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing surgery for hip replacement [abstract no. 190]. Pharmacotherapy 2003 Oct; 23 (10): 1355
67. Sullivan SD, Kahn SR, Muntz JE. Fondaparinux is cost-effective compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing surgery for knee replacement [abstract no. 191]. Pharmacotherapy 2003 Oct; 23 (10): 1355
68. Sullivan SD, Kahn SR, Muntz JE. Fondaparinux is cost-effective compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing surgery for hip fracture [abstract no. 189]. Pharmacotherapy 2003 Oct; 23 (10): 1355
69. Sullivan SD, Kwong L. A cost effectiveness analysis of extending prophylaxis from one week to four weeks with fondaparinux after hip fracture surgery [abstract no. 1827]. Blood 2003 Nov 16; 102 (11 Pt 1): 502a
70. Sullivan SD, Kwong L. Extended prophylaxis treatment with fondaparinux is cost effective compared with enoxaparin after hip fracture surgery [abstract no. 5771]. Blood 2003 Nov 16; 102 (11 Pt 2): 510b
71. Sullivan SD, Kwong L. The incremental cost per life year saved of extended prophylaxis with fondaparinux versus enoxaparin after hip fracture surgery [abstract no. 1826]. Blood 2003 Nov 16; 102 (11 Pt 1): 502a
72. Van Hout BA, Minjoulat-Rey MC, Quinlan DJ, et al. Cost-effectiveness of extending prophylaxis with fondaparinux in preventing venous thromboembolism following hip fracture surgery [poster]. 6th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; 2003 Nov 9-11; Barcelona
73. Sanofi-Synthelabo. Arixtra® in the European Union: New treatment duration for the prophylaxis of venous thromboembolic events in patients undergoing major orthopaedic surgery [online]. Available from URL: http://en.sanofi-synthelabo.com [Accessed 2003 Dec 3]
74. Nicolaides AN, Breddin HK, Fareed J, et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001 Mar; 20 (1): 1-37
75. de Moerloose P, Boehlen F. Two new antithrombotic agents (fondaparinux and ximelagatran) and their implications in anesthesia. Can J Anesth 2002; 49 (6): S5-S10
76. Mant M, Geerts B. The Thrombosis Interest Group of Canada. Practical treatment guidelines. DVT prophylaxis in orthopedics [online]. Available from URL: http://www.tigc.org/ eguidelines/dvtortho03.htm [Accessed 2003 Dec 17]
77. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001 Jul; 358: 9-15
78. D'Amico EA, Villaça PR, Gualandro SFM, et al. Successful use of Arixtra® in a patient with paroxysmal nocturnal hemoglobinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia [letter]. J Thromb Haemost 2003 Nov; 1 (11): 2452-3